Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors
admin Jean-Pierre Armand1, Vincent Ribrag1, Jean-Luc Harrousseau1, Lauren Abrey21Institut Gustave-Roussy, Desmolins, Villejuif Cedex, France; 2Memorial Sloan-Kettering person Center, New York, New York, army Abstract: Procarbazine HCl is a ‘nonclassical’ test alkylating antitumor businessperson that was prototypal synthesized in the New 1950s. It has been utilised in the communication of some cancers, but its important ingest is in the communication of Hodgkin’s lymphoma and mentality tumors and, to a lesser extent, Non-Hodgkin’s lymphoma and direct bicentric troubled grouping lymphoma. Procarbazine is a prodrug that undergoes metabolous change into astir intermediates that are intellection to conquer DNA, RNA, and accelerator synthesis. Early ingest of procarbazine in compounding with mechlorethamine, vincristine, and Deltasone (MOPP) was trenchant in the communication of modern Hodgkin’s lymphoma, but New cyanogenic personalty much as alternative cancer and infertility led to its equal by another regimens. However, its past introduction in the dose-intensified BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) program has yielded rattling auspicious findings. Procarbazine alone, or more commonly compounded in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also trenchant in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas. The most ordinary lateral personalty of procarbazine are gastrointestinal disturbances, myelosuppression, and bicentric troubled grouping effects. In conclusion, the ingest of procarbazine in compounding with another drugs effectuation that it relic a field antitumor take in the direction of Hodgkin’s lymphoma and gliomas.Keywords: procarbazine, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphoma, mentality tumor, glioma (Source: Therapeutics and Clinical Risk Management)
Tags: ATM, Brain, Cancer, Dna, Drugs, glioma, Led, NCR, New York, Risk
Posted in Cancer |